gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CDIOHealthcareDiagnostics

Cardio Diagnostics Holdings Inc. Common stock (CDIO)

$1.60−4.19%
Close Nov 3, 2026 · split-adjusted
Nov 3, 2026$1.60▼ 59.80% in range
Nov 3, 2025Low $1.05 · High $6.55Nov 3, 2026
What changed · written from our data
As of Nov 3, 2026

Cardio Diagnostics Holdings closed at $1.60 on Nov 3, down 4.19%, 75.6% below its 52-week closing high. Volume of 7.8K shares was 0.33× its 20-day average (below normal).

Split-adjusted performance: -22.3% over one month, -12.6% over six months, -60.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $5.36K, down 28.3% from a year earlier, with a net margin of -28012.5%.

Short interest was 3.0K shares at the Oct 15 settlement, up 193.6% from the prior report (0.1% of float, 1.0 days to cover).

Market cap$4.7M3.0M shares
Revenue · quarter$5.4K−28.3% YoY
Diluted EPS$-0.51—
P/E · TTM—P/S 327.7×
Net margin-28,012.5%Gross 100.0%
Dividend yieldNone
52-week range1.05 – 6.55−75.6% from high
Volume7.8K0.33× 20-day avg
Volatility · 60d66.7%Annualised
Short % of float0.1%1.0 days to cover
Net cash$5.6MCash $5.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −5.9%1M −22.3%3M −8.6%6M −12.6%YTD −41.0%1Y −60.4%3Y −76.7%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum29
Revenue growth25
Net margin8
Value (low P/E)—
Size7

Industry medians: 6-month return +15.3%, revenue growth −2.0%, net margin −26.0%, P/E 44.8×.

Short interest

Details →
Shares short3.0K+193.6% vs prior
Days to cover1.0Settled Oct 15
% of float0.1%
Short vol. 10d42.5%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CDIOCardio Diagnostics Holdings$1.60−4.19%−12.6%−28.3%−28012.5%—$4.7M
VNRXVolitionRx Limited$0.1930−8.14%−91.7%−2.0%−1953.1%—$5.8MCompare
QCLSQ/C Technologies$0.4250+1.19%−88.8%———$3.5MCompare
BMRABIOMERICA$1.70−1.73%−22.2%−8.3%−97.4%—$7.8MCompare
IMDXInsight Molecular Diagnostics$2.74−4.20%−40.2%−53.9%−4711.3%—$89.7MCompare
ICCCImmucell$10.25−2.94%+15.3%+11.5%25.5%118.2$93.1MCompare
TKNOAlpha Teknova$7.34+4.71%+96.3%+18.5%−26.0%—$452.9MCompare
MYGNMyriad Genetics$6.04+3.25%+20.1%−10.5%−22.7%—$577.7MCompare
ACHVAchieve Life Sciences$6.73+1.82%+47.6%———$693.9MCompare

News about Cardio Diagnostics Holdings

All news →

No recent articles focused on Cardio Diagnostics Holdings.

Quick answers

What does Cardio Diagnostics Holdings do?
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks.
What is CDIO's market cap?
$4.74M, based on the Nov 3 close of $1.60.
Does Cardio Diagnostics Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CDIO is sold short?
3.0K shares, 0.1% of float, as of Oct 15, 2026.
What sector is CDIO in?
Healthcare, in the Diagnostics industry.

About Cardio Diagnostics Holdings

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

HQ: Chicago, IL17 employeesListed Oct 26, 2022cdio.ai

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology